[1] C. Valkenborgh, L. Médart, L. Collignon, Muscle Metastasisfrom Undifferentiated (Anaplastic) Thyroid Carcinoma, Journal ofthe Belgian Society of Radiology. 103 (2019) 27.doi:10.5334/jbsr.1604.
[2] H. Yamazaki, H. Iwasaki, N. Suganuma, S. Toda, K. Masudo, H.Nakayama, Y. Rino, M. Masuda, Anaplastic thyroid carcinomadiagnosed after treatment of lenvatinib for papillary thyroidcarcinoma, Endocrinology, Diabetes & Metabolism Case Reports. 2019(2019). doi:10.1530/EDM-19-0085.
[3] D. Shelly, D. Gupta, S. Mishra, R. Bharadwaj, Osteoclasticvariant of anaplastic thyroid carcinoma: A case report of rareentity., Journal of Cancer Research and Therapeutics. 15 (2019)704–707. doi:10.4103/jcrt.jcrt_355_16.
[4] E. Spartalis, D.I. Athanasiadis, D. Chrysikos, M. Spartalis,G. Boutzios, D. Schizas, N. Garmpis, C. Damaskos, S.A. Paschou, A.Ioannidis, G. Tsourouflis, D. Dimitroulis, N.I. Nikiteas, HistoneDeacetylase Inhibitors and Anaplastic Thyroid Carcinoma, AnticancerResearch. 39 (2019) 1119–1127. doi:10.21873/anticanres.13220.
[5] L. Gou, H. Zou, B. Li, Long noncoding RNA MALAT1 knockdowninhibits progression of anaplastic thyroid carcinoma by regulatingmiR-200a-3p/FOXA1, Cancer Biology & Therapy. 20 (2019) 1355–1365.doi:10.1080/15384047.2019.1617567.
[6] J.-Y. Kim, H.Y. Youn, J. Choi, S.K. Baek, S.Y. Kwon, B.K.Eun, J.-Y. Park, K.H. Oh, Anoctamin-1 affects the migration andinvasion of anaplastic thyroid carcinoma cells, Animal Cells andSystems. 23 (2019) 294–301. doi:10.1080/19768354.2019.1614981.
[7] Z. Pan, L. Li, Q. Fang, Y. Qian, Y. Zhang, J. Zhu, M. Ge, P.Huang, Integrated Bioinformatics Analysis of Master Regulators inAnaplastic Thyroid Carcinoma, BioMed Research International. 2019(2019) 9734576. doi:10.1155/2019/9734576.
[8] R. Eshraghi, G.A. Barkan, S.E. Pambuccian, Rhabdoid cells inthe fine needle aspirate of a neck mass in a patient with historyof melanoma: Anaplastic thyroid carcinoma, DiagnosticCytopathology. 47 (2019) 1232–1236. doi:10.1002/dc.24284.
[9] C. Jiao, L. Li, P. Zhang, L. Zhang, K. Li, R. Fang, L. Yuan,K. Shi, L. Pan, Q. Guo, X. Gao, G. Chen, S. Xu, Q. Wang, D. Zuo, W.Wu, S. Qiao, X. Wang, R. Moses, J. Xiao, L. Li, Y. Dang, X. Li,REGγ ablation impedes dedifferentiation of anaplastic thyroidcarcinoma and accentuates radio-therapeutic response by regulatingthe Smad7-TGF-β pathway, Cell Death and Differentiation. (2019).doi:10.1038/s41418-019-0367-9.
[10] A.A.L. Chavez, P. Iyer, I.M. Cazacu, M.E. Cabanillas, A.Rashid, M.S. Bhutani, Anaplastic Thyroid Carcinoma with GastricMetastasis, Current Health Sciences Journal. 44 (2018) 294–298.doi:10.12865/CHSJ.44.03.14.
[11] Z. Li, Y. Zhang, R. Wang, K. Zou, L. Zou, Geneticalterations in anaplastic thyroid carcinoma and targeted therapies,Experimental and Therapeutic Medicine. 18 (2019) 2369–2377.doi:10.3892/etm.2019.7869.
[12] A. Fomenko, A.M. Lozano, Neuromodulation and ablation withfocused ultrasound - toward the future of noninvasive braintherapy, Neural Regeneration Research. 14 (2019) 1509–1510.doi:10.4103/1673-5374.255961.
[13] T. Lemaire, E. Neufeld, N. Kuster, S. Micera, Understandingultrasound neuromodulation using a computationally efficient andinterpretable model of intramembrane cavitation, Journal of NeuralEngineering. 16 (2019) 46007. doi:10.1088/1741-2552/ab1685.
[14] Z. Liu, H. Ran, Z. Wang, S. Zhou, Y. Wang, Targeted andpH-facilitated theranostic of orthotopic gastric cancer viaphase-transformation doxorubicin-encapsulated nanoparticlesenhanced by low-intensity focused ultrasound (LIFU) with reducedside effect, International Journal of Nanomedicine. 14 (2019)7627–7642. doi:10.2147/IJN.S212888.
[15] A. Fomenko, C. Neudorfer, R.F. Dallapiazza, S.K. Kalia,A.M. Lozano, Low-intensity ultrasound neuromodulation: An overviewof mechanisms and emerging human applications, Brain Stimulation.11 (2018) 1209–1217. doi:10.1016/j.brs.2018.08.013.
[16] K. Schindler, R. Wiest, M. Kollar, F. Donati, EEG analysiswith simulated neuronal cell models helps to detect pre-seizurechanges, Clinical Neurophysiology : Official Journal of theInternational Federation of Clinical Neurophysiology. 113 (2002)604–614. doi:10.1016/s1388-2457(02)00032-9.
[17] K. Schindler, R. Wiest, M. Kollar, F. Donati, Usingsimulated neuronal cell models for detection of epileptic seizuresin foramen ovale and scalp EEG, Clinical Neurophysiology : OfficialJournal of the International Federation of ClinicalNeurophysiology. 112 (2001) 1006–1017.doi:10.1016/s1388-2457(01)00522-3.
[18] J. Simões-Pereira, R. Capitão, E. Limbert, V. Leite,Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decadesat a Single Oncology Referral Centre and Novel Therapeutic Options,Cancers. 11 (2019). doi:10.3390/cancers11081188.
[19] J. Ljubas, T. Ovesen, M. Rusan, A Systematic Review ofPhase II Targeted Therapy Clinical Trials in Anaplastic ThyroidCancer, Cancers. 11 (2019). doi:10.3390/cancers11070943.
[20] J. Jin, X. Wu, J. Yin, M. Li, J. Shen, J. Li, Y. Zhao, Q.Zhao, J. Wu, Q. Wen, C.H. Cho, T. Yi, Z. Xiao, L. Qu,Identification of Genetic Mutations in Cancer: Challenge andOpportunity in the New Era of Targeted Therapy, Frontiers inOncology. 9 (2019) 263. doi:10.3389/fonc.2019.00263.
[21] C. Garcia, C. Buffet, L. El Khattabi, M. Rizk-Rabin, K.Perlemoine, B. Ragazzon, J. Bertherat, F. Cormier, L. Groussin, METoverexpression and activation favors invasiveness in a model ofanaplastic thyroid cancer, Oncotarget. 10 (2019) 2320–2334.doi:10.18632/oncotarget.26798.
[22] W. Qiu, C. Zhang, S. Wang, X. Yu, Q. Wang, D. Zeng, P. Du,J. Ma, Y. Zheng, B. Pang, Y. Yu, F. Long, X. Pang, Z. Sun, A NovelAnti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy thanCetuximab When Combined with Irinotecan, Journal of ImmunologyResearch. 2019 (2019) 3017360. doi:10.1155/2019/3017360.
[23] Y. Zhu, J. Li, F. Jing, T. Ji, X. Guo, J. Yang, S. Jiao,Evaluation of the immune factors in the tumor environment beforeand after the treatment of cetuximab combined with chemotherapy,World Journal of Surgical Oncology. 11 (2013) 226.doi:10.1186/1477-7819-11-226.
[24] B. Cáceres, A. Ramirez, E. Carrillo, G. Jimenez, C.Griñán-Lisón, E. López-Ruiz, Y. Jiménez-Martínez, J.A. Marchal, H.Boulaiz, Deciphering the Mechanism of Action Involved in EnhancedSuicide Gene Colon Cancer Cell Killer Effect Mediated by Gef andApoptin, Cancers. 11 (2019). doi:10.3390/cancers11020264.
[25] K.E. Boyle, Z.W. Patinkin, A.L.B. Shapiro, C. Bader, L.Vanderlinden, K. Kechris, R.C. Janssen, R.J. Ford, B.K. Smith, G.R.Steinberg, E.J. Davidson, I. V Yang, D. Dabelea, J.E. Friedman,Maternal obesity alters fatty acid oxidation, AMPK activity, andassociated DNA methylation in mesenchymal stem cells from humaninfants, Molecular Metabolism. 6 (2017) 1503–1516.doi:10.1016/j.molmet.2017.08.012.
[26] F. Wang, M. Porter, A. Konstantopoulos, P. Zhang, H. Cui,Preclinical development of drug delivery systems forpaclitaxel-based cancer chemotherapy, Journal of ControlledRelease : Official Journal of the Controlled Release Society. 267(2017) 100–118. doi:10.1016/j.jconrel.2017.09.026.
[27] M.C. Prewett, A.T. Hooper, R. Bassi, L.M. Ellis, H.W.Waksal, D.J. Hicklin, Enhanced antitumor activity of anti-epidermalgrowth factor receptor monoclonal antibody IMC-C225 in combinationwith irinotecan (CPT-11) against human colorectal tumor xenografts,Clinical Cancer Research : An Official Journal of the AmericanAssociation for Cancer Research. 8 (2002) 994–1003.http://europepmc.org/abstract/MED/12006511.
[28] N.A. Zaidman, A. Panoskaltsis-Mortari, S.M. O’Grady,Differentiation of human bronchial epithelial cells: role ofhydrocortisone in development of ion transport pathways involved inmucociliary clearance, American Journal of Physiology. CellPhysiology. 311 (2016) C225-36. doi:10.1152/ajpcell.00073.2016.
[29] C.-Q. Huang, Y. Min, S.-Y. Wang, X.-J. Yang, Y. Liu, B.Xiong, Y. Yonemura, Y. Li, Cytoreductive surgery plus hyperthermicintraperitoneal chemotherapy improves survival for peritonealcarcinomatosis from colorectal cancer: a systematic review andmeta-analysis of current evidence, Oncotarget. 8 (2017)55657–55683. doi:10.18632/oncotarget.17497.
[30] S. Ishihara, N. Onoda, S. Noda, Y. Asano, Y. Tauchi, T.Morisaki, S. Kashiwagi, T. Takashima, M. Ohira, Sorafenib inhibitsvascular endothelial cell proliferation stimulated by anaplasticthyroid cancer cells regardless of BRAF mutation status,International Journal of Oncology. 55 (2019) 1069–1076.doi:10.3892/ijo.2019.4881.
[31] J.R. Wang, M.E. Zafereo, R. Dadu, R. Ferrarotto, N.L.Busaidy, C. Lu, S. Ahmed, M.K. Gule-Monroe, M.D. Williams, E.M.Sturgis, R.P. Goepfert, N.D. Gross, S.Y. Lai, G.B. Gunn, J. Phan,D.I. Rosenthal, C.D. Fuller, W.H. Morrison, P. Iyer, M.E.Cabanillas, Complete Surgical Resection Following NeoadjuvantDabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic ThyroidCarcinoma, Thyroid : Official Journal of the American ThyroidAssociation. 29 (2019) 1036–1043. doi:10.1089/thy.2019.0133.
[32] K.L. Corrigan, H. Williamson, D. Elliott Range, D.Niedzwiecki, D.M. Brizel, Y.M. Mowery, Treatment Outcomes inAnaplastic Thyroid Cancer, Journal of Thyroid Research. 2019 (2019)8218949. doi:10.1155/2019/8218949.
[33] J.W. Bi, Y.L. Zou, J.T. Qian, W. Bin Chen, MiR-599 serves asuppressive role in anaplastic thyroid cancer by activating theT-cell intracellular antigen, Experimental and TherapeuticMedicine. 18 (2019) 2413–2420. doi:10.3892/etm.2019.7864.
[34] X. Wu, A. Benov, D.N. Darlington, J.D. Keesee, B. Liu, A.P.Cap, Effect of tranexamic acid administration on acute traumaticcoagulopathy in rats with polytrauma and hemorrhage, PloS One. 14(2019) e0223406. doi:10.1371/journal.pone.0223406.
[35] E.R. McGonagle, C. Nucera, Clonal Reconstruction of ThyroidCancer: An Essential Strategy for Preventing Resistance toUltra-Precision Therapy, Frontiers in Endocrinology. 10 (2019) 468.doi:10.3389/fendo.2019.00468.
[36] C.K. Song, S.H. Jung, D.-D. Kim, K.-S. Jeong, B.C. Shin, H.Seong, Disaccharide-modified liposomes and their in vitrointracellular uptake, International Journal of Pharmaceutics. 380(2009) 161–169. doi:10.1016/j.ijpharm.2009.07.014.
[37] M. Lei, G. Ma, S. Sha, X. Wang, H. Feng, Y. Zhu, X. Du,Dual-functionalized liposome by co-delivery of paclitaxel withsorafenib for synergistic antitumor efficacy and reversion ofmultidrug resistance, Drug Delivery. 26 (2019) 262–272.doi:10.1080/10717544.2019.1580797.
[38] Y. Wang, Y. Yang, Y. Yu, J. Li, W. Pan, X. Yang, Z. Zhang,S. Jiang, X. Yang, X. Wang, Transferrin Modified Dioscin LoadedPEGylated Liposomes: Characterization and In Vitro AntitumorEffect, Journal of Nanoscience and Nanotechnology. 20 (2020)1321–1331. doi:10.1166/jnn.2020.16955.
[39] M.S. Mohamed Kasim, S. Sundar, R. Rengan, Synthesis andstructure of new binuclear ruthenium(II) arene benzilbis(benzoylhydrazone) complexes: Investigation on antiproliferativeactivity and apoptosis induction, Inorganic Chemistry Frontiers. 5(2018) 585–596. doi:10.1039/c7qi00761b.
[40] M.K. Mohamed Subarkhan, L. Ren, B. Xie, C. Chen, Y. Wang,H. Wang, Novel tetranuclear ruthenium(II) arene complexes showingpotent cytotoxic and antimetastatic activity as well as lowtoxicity in vivo, European Journal of Medicinal Chemistry. 179(2019) 246–256.doi:https://doi.org/10.1016/j.ejmech.2019.06.061.
[41] M.K. Mohamed Subarkhan, R. Ramesh, Y. Liu, Synthesis andmolecular structure of arene ruthenium(ii) benzhydrazone complexes:impact of substitution at the chelating ligand and arene moiety onantiproliferative activity, New Journal of Chemistry. 40 (2016)9813–9823. doi:10.1039/C6NJ01936F.
[42] X.-L. Pang, G. He, Y.-B. Liu, Y. Wang, B. Zhang,Endoplasmic reticulum stress sensitizes human esophageal cancercell to radiation, World Journal of Gastroenterology. 19 (2013)1736–1748. doi:10.3748/wjg.v19.i11.1736.
[43] V. Ramalingam, S. Revathidevi, T. Shanmuganayagam, L.Muthulakshmi, R. Rajaram, Biogenic gold nanoparticles induce cellcycle arrest through oxidative stress and sensitize mitochondrialmembranes in A549 lung cancer cells, RSC Advances. 6 (2016)20598–20608. doi:10.1039/C5RA26781A.
[44] C. Huang, Y. Sun, M. Shen, X. Zhang, P. Gao, Y. Duan,Altered Cell Cycle Arrest by Multifunctional Drug-LoadedEnzymatically-Triggered Nanoparticles, ACS Applied Materials &Interfaces. 8 (2016) 1360–1370. doi:10.1021/acsami.5b10241.
[45] B.L. Allen-Petersen, R.C. Sears, Mission Possible: Advancesin MYC Therapeutic Targeting in Cancer, BioDrugs : ClinicalImmunotherapeutics, Biopharmaceuticals and Gene Therapy. 33 (2019)539–553. doi:10.1007/s40259-019-00370-5.
[46] M. Li, Y. Ning, J. Chen, X. Duan, N. Song, D. Ding, X. Su,Z. Yu, Proline Isomerization-Regulated TumorMicroenvironment-Adaptable Self-Assembly of Peptides for EnhancedTherapeutic Efficacy, Nano Letters. (2019).doi:10.1021/acs.nanolett.9b03136.
[47] C. Scottà, G. Fanelli, S.J. Hoong, M. Romano, E.N.Lamperti, M. Sukthankar, G. Guggino, H. Fazekasova, K. Ratnasothy,P.D. Becker, B. Afzali, R.I. Lechler, G. Lombardi, Impact ofimmunosuppressive drugs on the therapeutic efficacy of ex vivoexpanded human regulatory T cells, Haematologica. 101 (2016)91–100. doi:10.3324/haematol.2015.128934.
[48] R. Bharadwaj, B.P. Sahu, J. Haloi, D. Laloo, P. Barooah, C.Keppen, M. Deka, S. Medhi, Combinatorial therapeutic approach fortreatment of oral squamous cell carcinoma, Artificial Cells,Nanomedicine, and Biotechnology. 47 (2019) 572–585.doi:10.1080/21691401.2019.1573176.
[49] X. Chen, W. Wu, S. Wang, J. Zhong, N.M. Djama, G. Wei, Y.Lai, X. Si, S. Cao, W. Liao, Y. Liao, H. Li, J. Bin, MagneticTargeting Improves the Therapeutic Efficacy of Microbubble-MediatedObstructive Thrombus Sonothrombolysis, Thrombosis and Haemostasis.(2019). doi:10.1055/s-0039-1695767.
[50] M.A. Vakilinezhad, A. Amini, T. Dara, S. Alipour,Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as apotential breast cancer therapeutic system: In vitro and in vivoevaluation, Colloids and Surfaces. B, Biointerfaces. 184 (2019)110515. doi:10.1016/j.colsurfb.2019.110515.
[51] V. Gies, S. Zou, Systematic toxicity investigation ofgraphene oxide: evaluation of assay selection, cell type, exposureperiod and flake size, Toxicology Research. 7 (2018) 93–101.doi:10.1039/c7tx00278e.
[52] A. Bathla, R.A. Rather, T. Poonia, B. Pal, MorphologyDependent Photocatalytic Activity of CuO/CuO-TiO₂ Nanocatalyst forDegradation of Methyl Orange Under Sunlight, Journal of Nanoscienceand Nanotechnology. 20 (2020) 3123–3130.doi:10.1166/jnn.2020.17397.
[53] A.Y. Xu, M.M. Castellanos, K. Mattison, S. Krueger, J.E.Curtis, Studying Excipient Modulated Physical Stability andViscosity of Monoclonal Antibody Formulations Using Small-AngleScattering, Molecular Pharmaceutics. 16 (2019) 4319–4338.doi:10.1021/acs.molpharmaceut.9b00687.
[54] Z. Cui, X. Zhang, X. Zhang, S. He, W. Gao, B. He, X. Wang,H. Zhang, Z. Zhong, Q. Zhang, Visualizing in vitro-in vivocorrelation of miktoarm copolymer nanomicelles in cancer cellularuptake and trafficking, (2019). doi:10.1101/755595.
[55] Y. Chen, Y. Liang, P. Jiang, F. Li, B. Yu, F. Yan,Lipid-PLGA hybrid microbubbles as a versatile platform fornon-invasive image-guided targeted drug delivery, ACS AppliedMaterials & Interfaces. (2019). doi:10.1021/acsami.9b10188.
[56] Y. Liu, S. Chen, J. Sun, S. Zhu, C. Chen, W. Xie, J. Zheng,Y. Zhu, L. Xiao, L. Hao, Z. Wang, S. Chang, Folate-Targeted andOxygen/Indocyanine Green-Loaded Lipid Nanoparticles for Dual-ModeImaging and Photo-sonodynamic/Photothermal Therapy of OvarianCancer in Vitro and in Vivo, Molecular Pharmaceutics. 16 (2019)4104–4120. doi:10.1021/acs.molpharmaceut.9b00339.
[57] H. Yang, W. Cai, W. Lv, P. Zhao, Y. Shen, L. Zhang, B. Ma,L. Yuan, Y. Duan, K. Yao, A new strategy for accurate targeteddiagnosis and treatment of cutaneous malignant melanoma: dual-modephase-change lipid nanodroplets as ultrasound contrast agents,International Journal of Nanomedicine. 14 (2019) 7079–7093.doi:10.2147/IJN.S207419.